Complete Genomics

Novogene uses leading technology from Illumina, Pacific Biosciences, Oxford Nanopore and Life Technologies, in our state-of-the-art sequencing centers in California (USA), Cambridge (UK), Singapore and China. Reliable and high quality NGS data is a key component in genomics research. At Novogene, we use the most effective technology available from world leading providers including Illumina NovaSeq 6000, HiSeq, Oxford Nanopore, Ion Torrent , PacBio Revio and PacBio Sequel platforms. Over the years our NGS labs have developed optimized NGS processes and protocols to ensure the best possible scientific outcome for your research. Not only do we offer state of the art NGS technology, we also have the largest sequencing capacity in the world with an annual throughput of over 280,000 human WGS samples.

We are committed to answer our client's questions quickly and accurately. Currently, we are developing next-generation medicines for people suffering from cancer, chronic and rare diseases worldwide. We provide next-generation sequencing services on next-generation sequencing platforms (NGS), including proprietary technology platforms that offer quality data at unbeatable prices for a wide variety of sequencing services and clinical applications. All quality controls are built into our procedures at every step. Offering unrivaled flexibility in diagnostic testing, and affordable genomic sequencing. Our team of medical experts has developed reliable, comprehensive and actionable genetic tests, using next-generation sequencing of the genome and individual cells by using any of our 18000+ genes. Diploide is a leading provider of genomic services and solutions with next-generation NGS with the most extensive experience in bioinformatics, and the most advanced sequencing capability in the world. We offer a wide range of next-generation sequencing services with the world's largest portfolio of genetic testing panels, enhanced with the ability to develop algorithms, chips, specific and / or specialized arrangements for medical institutions, research institutions and other partners.

We are skilled in delivering high-quality next-generation sequencing data from RNA and DNA samples, using Illumina NovaSeq and MiSeq platforms. The facility operates the PacBio Revio and the Oxford Nanopore PromethION for long read sequencing.

Through innovative clinicaland food safetynext-generation sequencing and software, we deliver clarityin infectious disease genome surveillance that can help protect human lives. Increase lab tech efficiency and productivity with our comprehensive and user-friendly next-generation sequencing platform.

We are developing novel genomic tools to reveal DNA alterations with unprecedented accuracy for clinical and research use. Point-n-Seq is the first technology that can conduct a combined methylation and genomic alteration analysis without having to split samples.

Our mission is to bring dramatic, life-changing improvements to healthcare and beyond with fast, simple and scientifically sound products. DNAe Group Holdings LtdScale Space58 Wood Lane London W12 7RZ United Kingdom. At DNAe we are leading the way in rapid, near-patient sequencing testing that will revolutionize patient care for a range of unmet clinical needs. DNAe is developing the LiDia-SEQ™ Platform, a direct-from-specimen diagnostic system that performs DNA sequencing on a microchip, to provide rapid, actionable information to clinicians. We are creating radically different products that change the game for early diagnosis and monitoring of potentially fatal diseases. Regius Professor Chris Toumazou FRS, FREng, FMedSci founded the company in 2003, as a spin-out from Imperial College London, having invented a way of detecting protons released during DNA synthesis to enable DNA sequence detection using a standard silicon-chip based transistor. Regius Professor Chris Toumazou FRS, FREng, FMedSci founded the company in 2003, as a spin-out from Imperial College, London, having invented a way of detecting protons released during DNA synthesis to enable DNA sequence detection using a standard silicon-chip based transistor. The user-friendly system can operate in a variety of hospital environments at the point-of-need, with flexible levels of throughput to match a wide range of clinical demands.‍Our initial focus is on infectious disease diagnostics, where speed and microbial DNA sequence information can make the difference between life and death.